Defunct Company
Total Trials
8
As Lead Sponsor
As Collaborator
0
Total Enrollment
1,202
NCT01949883
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
Phase: Phase 1
Role: Lead Sponsor
Start: Sep 5, 2013
Completion: Dec 20, 2017
NCT02157636
A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma
Start: Jul 15, 2014
Completion: Nov 8, 2016
NCT02158858
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Phase: Phase 1/2
Start: Jul 16, 2014
Completion: Jan 9, 2025
NCT02395601
A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas
Start: Mar 31, 2015
Completion: Dec 31, 2018
NCT03480646
ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer
Start: Nov 15, 2017
Completion: Dec 31, 2021
NCT03525795
ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors
Start: Dec 14, 2017
Completion: Jun 12, 2019
NCT04603495
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
Phase: Phase 3
Start: Apr 9, 2021
Completion: Dec 31, 2027
NCT05391022
Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies
Start: Jul 20, 2021
Completion: Feb 29, 2024